Cargando…

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Su-Gang, Wang, Lan, Pudasaini, Bigyan, Yuan, Ping, Jiang, Rong, Zhao, Qin-Hua, He, Jing, Zhang, Rui, Wu, Wen-hui, Liu, Jin-Ming, Zhou, Cai-cun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924990/ https://www.ncbi.nlm.nih.gov/pubmed/29849836 http://dx.doi.org/10.1155/2018/9836820

Ejemplares similares

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
por: Safdar, Zeenat
Publicado: (2011)

Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009)

Diffuse Pulmonary Arteriovenous Fistulas With Pulmonary Arterial Hypertension: Case Report and Review
por: Jiang, Rong, et al.
Publicado: (2016)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
por: Li, Xinmei, et al.
Publicado: (2020)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients
por: Pudasaini, Bigyan, et al.
Publicado: (2018)

Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
por: Lepist, Eve-Irene, et al.
Publicado: (2014)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009)

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension
por: Lee, Young Ho, et al.
Publicado: (2013)

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension
por: Amin, Ahmad, et al.
Publicado: (2015)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

The Correlation of Decreased Heart Rate Recovery and Chronotropic Incompetence with Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension Patients
por: Wu, Changwei, et al.
Publicado: (2017)

Sex-specific cardiopulmonary exercise testing indices related to hemodynamics in idiopathic pulmonary arterial hypertension
por: Yuan, Ping, et al.
Publicado: (2017)

A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension
por: Xiong, Wei, et al.
Publicado: (2018)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Sex-specific cardiopulmonary exercise testing indices to estimate the severity of inoperable chronic thromboembolic pulmonary hypertension
por: Chen, Tian-Xiang, et al.
Publicado: (2018)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study
por: Huo, Y., et al.
Publicado: (2016)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Survival in severe pulmonary hypertension due to chronic lung disease: influence of in-hospital platelet distribution width
por: Wang, Lan, et al.
Publicado: (2021)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
por: Jasenovec, Tomas, et al.
Publicado: (2022)

Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis
por: Li, Mengtao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5j62b8acepgcjmuroq5agtvugf